Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Certara Inc (NQ: CERT )

10.25 +0.05 (+0.49%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Certara Inc

< Previous 1 2 Next >
Certara to Participate in the Stephens Annual Investment Conference
From Certara
Via GlobeNewswire
Certara Appoints John Reynders as New Independent Board Member
From Certara
Via GlobeNewswire
MaxCyte Appoints Cynthia Collins to its Board of Directors
From MaxCyte, Inc
Via GlobeNewswire
Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024
From Certara
Via GlobeNewswire
Certara Completes Acquisition of Chemaxon
The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through... 
From Certara
Via GlobeNewswire
Certara’s Simcyp Consortium Celebrates 25th Anniversary
The pre-competitive scientific research consortium of top pharmaceutical companies remains a critical force in advancing qualified PBPK modeling and simulation to further drug development and... 
From Certara
Via GlobeNewswire
Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug
Preclinical research on the trispecific antibody, ISB 2001, published in Nature Cancer leveraged virtual trials to select a higher starting dose that would lower costs and reduce cycle times 
From Certara
Via GlobeNewswire
Certara to Participate in Upcoming Investor Conferences
From Certara
Via GlobeNewswire
Certara Launches Phoenix™ Version 8.5 Drug Development Software
From Certara
Via GlobeNewswire
Certara Reports Second Quarter 2024 Financial Results
Reiterates Full Year 2024 Financial Guidance 
From Certara
Via GlobeNewswire
Certara to Acquire Chemaxon to Strengthen Drug Discovery Software Portfolio
From Certara
Via GlobeNewswire
Simulations Plus Stock Drops 15% Despite EPS Beat
Simulations Plus fell 15% the day after its earnings release despite beating EPS estimates due to lower margins and lower full-year guidance. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Certara to Report Second Quarter 2024 Financial Results on August 6th, 2024
From Certara
Via GlobeNewswire
Certara Launches Next Generation CoAuthor™ Generative AI Regulatory Writing Software
AI-enabled solutions accelerate regulatory and medical writing processes, enhancing quality, transparency, and efficiencies 
From Certara
Via GlobeNewswire
Certara to Participate in the Jefferies Global Healthcare Conference
From Certara
Via GlobeNewswire
Certara Appoints New Chief Human Resources Officer & General Counsel
From Certara
Via GlobeNewswire
Certara Reports First Quarter 2024 Financial Results
Reiterates Full Year 2024 Financial Guidance 
From Certara
Via GlobeNewswire
Certara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform
From Certara
Via GlobeNewswire
Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference
From Certara
Via GlobeNewswire
Certara Reports Fourth Quarter 2023 Financial Results
Provides Full Year 2024 Financial Guidance 
From Certara
Via GlobeNewswire
Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global Healthcare Conference
From Certara
Via GlobeNewswire
Certara Acquires Applied BioMath Expanding Its Biosimulation Portfolio to Industrialize New Capabilities for Optimal Dosing for Novel Therapies
Combined organization establishes the life sciences industry’s largest quantitative systems pharmacology (QSP) center of excellence contributing to faster and more effective medicine development. 
From Certara
Via GlobeNewswire
Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development
Simcyp Biopharmaceutics helps drug developers replace costly clinical bioequivalence studies and optimize formulations for complex therapies 
From Certara
Via GlobeNewswire
Certara Reports Third Quarter 2023 Financial Results
Reiterates Full Year 2023 Financial Guidance 
From Certara
Via GlobeNewswire
Certara to Report Third Quarter 2023 Financial Results on November 8th, 2023, and participate in the Stephens Annual Investment Conference
From Certara
Via GlobeNewswire
Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software
Dedicated team of global regulatory experts delivers submissions in increasingly shorter timelines 
From Certara
Via GlobeNewswire
Certara to Participate in Upcoming Investor Conferences
From Certara
Via GlobeNewswire
Certara Simcyp™ Group Awarded Two New Grants from US FDA
Programs focus on use of physiologically-based pharmacokinetic (PBPK) modeling for demonstrating virtual bioequivalence and predicting drug absorption of topical formulations 
From Certara
Via GlobeNewswire
Certara Reports Second Quarter 2023 Financial Results
Provides Update to Full Year 2023 Financial Guidance 
From Certara
Via GlobeNewswire
Certara to Report Second Quarter 2023 Financial Results on August 9th, 2023
From Certara
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.